Company: DMAAR
Filing Date: 2025-01-22
Form Type: POS AM
Source: 0001213900-25-005176
Chunk: 194

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-01-22
Form: POS AM
Chunk 194
---
 combination, or earlier, in either case, if, subsequent to our initial business combination, we consummate a liquidation, merger, share exchange or other similar transaction which results in all of our shareholders having the right to exchange their ordinary shares for cash, securities or other property. Since our initial shareholders, directors and officers may directly or indirectly own our securities following this offering, they may have a conflict of interest in determining whether a particular target business is an appropriate business with which to effectuate our initial business combination. •In the event that we submit our initial business combination to our public shareholders for a vote, our initial shareholders, directors and officers have agreed (and their permitted transferees will agree), pursuant to the terms written agreements entered into with us, to vote any founder shares and public shares held by them in favor of our initial business combination. •Our directors and officers may negotiate employment or consulting agreements with a target business in connection with a particular business combination. These agreements may provide for them to receive compensation following our initial business combination and as a result, may cause them to have conflicts of interest in determining whether to proceed with a particular business combination. The conflicts described above may not be resolved in our favor. As a result of multiple business affiliations, our directors and officers have now and may have in the future similar legal obligations to other companies that may require them to present business opportunities to those companies. Below is a table summarizing the entities to which our directors and officers currently have such duties:

| Individual        |     | Entity                      |     | Entity’s Business                   |     | Affiliation/Title                    |
| Lynn Stockwell    |     | Bright Green Corporation    |     | plant-based pharmaceutical company  |     | Chair of the Board                   |
| Glenn Worman      |     | SeatonHill Partners, LP     |     | CFO services firm                   |     | Partner                              |
|                   |     | Insight Acquisition Corp.   |     | special purpose acquisition company |     | Chief Financial Officer              |
| Catherine Do      |     | NYU Langone Health Hospital |     | hospital                            |     | Research Assistant Professor         |
| G. Sridhar Prasad |     | Ventus Therapeutics         |     | biopharmaceutical company           |     | Director and Head of Protein Science |
| Myron W. Shulgan  |     | Strosberg Sasso Sutts LLP   |     | law firm                            |     | Partner                              |

If any of our directors or officers become